Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Increases By 2,707.3%

Tharimmune, Inc. (NASDAQ:THAR) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 496,900 shares, a growth of 2,707.3% from the October 15th total of 17,700 shares. Based on an average trading volume of 1,010,000 shares, the short-interest ratio is presently 0.5 days. Approximately 44.0% of the company’s stock are sold short.

Tharimmune Stock Up 4.1 %

THAR stock traded up $0.09 on Thursday, reaching $2.27. 118,493 shares of the company traded hands, compared to its average volume of 331,032. Tharimmune has a one year low of $1.84 and a one year high of $79.65. The firm has a fifty day simple moving average of $2.47 and a 200-day simple moving average of $3.39.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Tharimmune stock. Curi RMB Capital LLC acquired a new stake in shares of Tharimmune, Inc. (NASDAQ:THAR) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned approximately 2.06% of Tharimmune as of its most recent SEC filing. 1.16% of the stock is owned by hedge funds and other institutional investors.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).